SHTDY SINOPHARM GROUP CO
- 12.835
- -0.903-6.57%
SINOPHARM GROUP CO News
Changes in Hong Kong stocks | Sinopharm Holdings (01099) fell more than 10% after results, net profit returned to mother fell by more than 10% year-on-year in the first quarter
Sinopharm Holdings (01099) fell by more than 10% after the results. As of press release, it was down 8.03% to HK$19.82, with a turnover of HK$113 million.
Sinopharm Holdings announced first-quarter results, net profit of about 1.42 billion yuan, a year-on-year decrease of 10.7%
Sinopharm Holdings (01099) announced its results for the first quarter of 2024, with total revenue of about 147.266 billion yuan, up 1.2% year on year; net profit attributable to owners of the parent company was about 1.42 billion yuan, a decrease of 10.7% year on year; basic earnings per share were 0.46 yuan.
Sinopharm Holdings (01099.HK): It is recommended to uniformly register and issue non-financial corporate debt financing instruments
Gelonghui, April 29, 丨 Sinopharm Holdings (01099.HK) issued an announcement. On April 26, 2024, the board of directors resolved to uniformly register and issue non-financial corporate debt financing instruments (TDFI) lines in China in order to meet the company's actual needs for supplementary operation and provision of funds, ensure smooth direct financing channels, reduce financing costs, and improve the debt structure. According to Chinese law and articles of association, the proposed amount for unified registration and issuance of non-financial corporate debt financing instruments must be reviewed and approved by shareholders in a special resolution and approved by the relevant Chinese regulatory authorities before implementation.
Sinopharm Holdings (01099) plans to uniformly register and issue 30 billion yuan of non-financial corporate debt financing instruments in China
Sinopharm Holdings (01099) announced that in order to meet the company's actual needs for supplementary operation and provision of capital, it guarantees direct financing channels...
Sinopharm Group 1Q Total Operating Revenue CNY147.27B Vs. CNY145.52B >1099.HK
Sinopharm Group 1Q Total Operating Revenue CNY147.27B Vs. CNY145.52B >1099.HK
Sinopharm Holdings (01099) announced first-quarter results, net profit of about 1.42 billion yuan, a year-on-year decrease of 10.7%
Sinopharm Holdings (01099) announced its results for the first quarter of 2024, with total revenue of about 147.266 billion yuan,...
國藥控股：公告 截至 2024 年 3 月 31 日止三個月之季度財務資料
國藥控股：年度報告2023
國藥控股：公告 國藥股份截至2024年3月31日止第一季度之 主要未經審核會計數據和財務指標
Sinopharm Holdings (01099): Sinopharm (000028.SZ) net profit of about 389 million yuan in the first quarter increased 7.33% year-on-year
Sinopharm Holdings (01099) announced Sinopharm's (000028.SZ) results for the first quarter of 2024, operating...
國藥控股：公告 國藥一致截至2024年3月31日止第一季度之 主要未經審核會計數據和財務指標
Hong Kong Stock Concept Tracking | The 2024 trend of mergers and acquisitions of pharmaceutical distribution companies is expected to further accelerate leading state-owned enterprises to attract attention (with concept stocks)
The trend of mergers and acquisitions of domestic pharmaceutical distribution companies is expected to accelerate further, and the concentration of leaders may further increase
SDIC Securities: The industry is heavily state-owned capital, and the trend of mergers and acquisitions of pharmaceutical distribution companies is expected to accelerate further in 24 years
The new round of state-owned enterprise reform also emphasizes specialized integration in the medical and health sector. The pharmaceutical distribution industry is heavily state-owned and driven by superposition policies. At the time point of 2024, the trend of mergers and acquisitions of domestic pharmaceutical distribution companies is expected to further accelerate.
[Broker Focus] CMB International expects China's pharmaceutical industry to return to healthy growth this year
Jinwu Financial News | CMB International said that since the beginning of the year, the MSCI China Healthcare Index has fallen 22.7%, outperforming the MSCI China Index by 23.3%. Looking ahead to 2024, China's pharmaceutical industry is expected to return to healthy growth as industry regulation is normalized and the impact of the COVID-19 base gradually subsides. The bank continues to be optimistic about BeiGene (06160), Cinda Biotech (01801), Columbotai (06990), Giant Biotech (02367), Gushengtang (02273), and Mindray Healthcare (300760). Additionally, it is recommended to focus on high-dividend stocks with steady performance, such as Regal Healthcare
Sinopharm Holdings (01099.HK) plans to hold a board meeting on April 26 to approve quarterly results
Gelonghui, April 16, 丨 Sinopharm Holdings (01099.HK) announced that the board of directors will hold a board meeting on April 26, 2024 (Friday) to consider and approve (including) the unaudited quarterly results of the company and its subsidiaries for the three months ended March 31, 2024.
國藥控股：董事會會議通告
Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it might
Sinopharm Holdings received 997,600 additional shares from FMR LLC at a price of approximately HK$20.49 per share
According to the latest data from the Hong Kong Stock Exchange, on April 2, FMR LLC increased its holdings of Sinopharm Holdings (01099) by 997,600 shares, at a price of HK$20.4938 per share, for a total amount of about HK$204.44,600. After the increase in holdings, the latest number of shares held was about 162 million shares, and the latest shareholding ratio was 12.04%.
Sinopharm Holdings (01099.HK) gains 997,600 shares from FMR LLC
Gelonghui, April 9 | According to the latest equity disclosure data on the Stock Exchange, on April 2, 2024, Sinopharm Holdings (01099.HK) received FMR LLC an increase of 997,600 shares at an average price of HK$20.4938 per share on the market, involving approximately HK$20.445 million. After the increase in holdings, FMR LLC's latest shareholding was 161,576,874 shares, and the shareholding ratio increased from 11.97% to 12.04%.
Sinopharm Holdings (01099): Sinopharm (000028.SZ)'s 2023 net profit of 1,599 billion yuan increased 7.57% year-on-year
Sinopharm Holdings (01099) issued an announcement. Sinopharm Group, a subsidiary of the company, is united Pharmaceutical Co., Ltd. (Sinopharm 1...
Analysis
Price Target
No Data
